Seeking Alpha
 

MELA Sciences, Inc. (MELA)

- NASDAQ
  • Jul. 22, 2014, 12:47 PM
    | 10 Comments
  • Jul. 3, 2014, 8:41 AM
    • Mela Sciences (MELA) will execute a one-for-ten reverse stock split effective at 5:00 pm EDT July 9, 2014. The reason for the reverse split is to enable the company to regain compliance with the NASDAQ's $1 minimum bid price requirement.
    • Post split trading will commence on July 10 under the same symbol.
    | 2 Comments
  • May 13, 2014, 5:00 PM
    • MELA Sciences (MELA): Q1 EPS of -$0.16.
    • Revenue of $97.64M (-3.22% Y/Y)
    • Press Release
    | Comment!
  • Mar. 17, 2014, 4:10 PM
    | Comment!
  • Jan. 2, 2014, 8:26 AM
    • MELA Sciences' (MELA) CFO Richard Steinhart resigns.
    • CEO Rose Crane will step in while the company searches for a replacement.
    • The company also says three members of its board have resigned "due to other professional commitments and a desire to streamline the Board to better reflect the company's current size."
    • Jeffrey ODonnell, Managing Director at BioStar Ventures, joins the Board. (PR)
    | 3 Comments
  • Aug. 7, 2013, 6:15 PM
    • MELA Sciences (MELA): Q2 EPS of -$0.17 in-line.
    • Revenue of $144.4K misses by $105.6K. (PR)
    | 2 Comments
  • Aug. 7, 2013, 4:27 PM
    • Mela Sciences (MELA), maker of the MelaFind system, posts revenue of $144K for Q2, well short of the $250K analysts expected.
    • Deferred revenues as of June 30 were $434,030.
    • The company is embarking on a restructuring effort in order to "focus on improving commercial execution and to position [itself] to support sustainable revenue growth and eventual profitability."
    • MELA says it will reduce its workforce by 25%. (PR)
    | Comment!
  • Jul. 21, 2013, 12:30 PM
    Shares of MELA Sciences (MELA) are on watch Monday after a NY Times article highlights the debate around MelaFind, the company's FDA approved melanoma-finding computer vision device which uses algorithms to pick out irregularities in pigmented skin legions. "My concern with MelaFind is that it just says everything is positive," one biostatistician who sat on the FDA review panel which evaluated the device says. "It will err on the side of caution," counters the company's director of commercialization. It will be interesting to see if the system can gain traction in what is quickly becoming a tough market for medical devices (I, II).
    | 4 Comments
  • Jun. 24, 2013, 1:19 PM
    MELA Sciences (MELA +5.6%) gets a pop after Interim CEO Robert Coradini disclosed the purchase of 50K shares today at an average price of $0.7198, bringing his stake to 71,457 shares. Director Kathryn Swintek also purchased 17K shares at $0.729.
    | Comment!
  • Jun. 5, 2013, 8:24 PM
    MELA Sciences (MELA) files a $75 million mixed securities shelf with the SEC. Shares -19% AH.
    | Comment!
  • May 1, 2013, 3:46 PM
    Mela Sciences (MELA -10.6%) takes a hit today after its Q1 revenue misses by a huge margin despite a nearly 12-fold increase over year-ago levels. Revenue for the three months ended March 31 totaled $144,100, up from $11,250 during the same quarter last year but still lagging the analyst consensus by more than 76%, as a sizeable chunk of the quarters revenue from Melafind sales were deferred.
    | 3 Comments
  • May 1, 2013, 4:42 AM
    MELA Sciences (MELA): Q1 EPS of -$0.17 beats by $0.01. Revenue of $144K misses by $466K. (PR)
    | 1 Comment
  • Mar. 6, 2013, 3:18 PM
    Mela Sciences (MELA -17%) reverses yesterday's post-session gains and sinks on a disappointing Q4. Higher marketing expenses, coupled with an increase in costs associated with installing its Melafinds systems in medical offices, all conspired to pressure margins.
    | Comment!
  • Mar. 5, 2013, 6:47 PM
    More on Mela Sciences (MELA): Q4 comes in line with estimates. Net loss for quarter was $6.1M, or $0.19 per diluted share, compared to a net loss of $4.5M, or $0.17 per diluted share for Q411. The higher net losses can be attributed to greater SG&A costs, and an increase in direct costs associated with the placement of MelaFind systems in dermatologists' offices. Total revenues were boosted by increased installation of its MelaFind, with 20 additional user agreements signed in Q4. Shares +4.2% AH.
    | Comment!
  • Mar. 5, 2013, 4:29 PM
    MELA Sciences (MELA): Q4 EPS of -$0.19 in-line. Revenue of $122.3K. Shares -3.4% AH. (PR)
    | 1 Comment
  • Feb. 12, 2013, 4:06 PM
    MELA Sciences (MELA -13%) finishes lower today after pricing its 6.1M share public offering at $1.30 per share, a 23% discount to yesterdays close. The company plans to use the funds for its commercial launch of MelaFind.
    | Comment!
Visit Seeking Alpha's
MELA vs. ETF Alternatives
Company Description
Mela Sciences Inc is a medical device company focused on the commercialization of its flagship product, MelaFind. MelaFind is a non-invasive, point-of-care instrument to aid in the detection of melanoma.